Product Description
Sodium chloride is an inorganic chloride salt having sodium(1+) as the counterion. It has a role as an emetic and a flame retardant. It is an inorganic chloride and an inorganic sodium salt. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Sodium-chloride)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous, Intramuscular, Subcutaneous
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Norgine
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Belgium, Brazil, Bulgaria, Chile, China, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, India, Ireland, Italy, Japan, Kenya, Latvia, Lithuania, Malawi, Mexico, Netherlands, Norway, Peru, Philippines, Poland, Portugal, Russia, Slovenia, South Africa, South Korea, Spain, Sweden, Taiwan, Uganda, United Kingdom, United States, Unknown Location, Zimbabwe
Active Clinical Trial Count: 115
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Abscess|Asthma, Allergic|Ataxia Telangiectasia|Cervical Cancer|Cervical Intraepithelial Neoplasia|Conjunctivitis, Allergic|Dermatomyositis|Dust mite Hypersensitivity|Emphysema|Endometritis|Environmental Hypersensitivity|Esophageal Cancer|Fallopian Tube Diseases|HIV Infections|Heart Failure|Herpes Zoster|Inflammation|Influenza, Human|Injuries/wounds Unspecified|Kidney Diseases|Lyme Disease|Meningitis|Necrotizing Autoimmune Myopathy|Neuralgia, Postherpetic|Non-Small-Cell Lung Cancer|Oophoritis|Other|Ovarian Diseases|Papillomavirus Infections|Peritonitis|Pleural Effusion, Malignant|Pneumonia|Polymyositis|Respiratory Syncytial Virus Infections|Respiratory Tract Infections|Rhinitis, Allergic|Salpingitis|Small Cell Lung Cancer|Small Fiber Neuropathy|Thyroid Eye Disease|Urinary Tract Infections|alpha 1-Antitrypsin Deficiency
Phase 2: Abdominal Pain|Acute Coronary Syndrome|Alzheimer Disease|Anesthesia Related|Atrial Fibrillation|Bronchopulmonary Dysplasia|Bunion|CADASIL|Cardiac Arrest|Chickenpox|Chronic Pain|Communicable Diseases|Crohn Disease|Fatty Liver, Alcoholic|Glabellar Reflex|Gonorrhea|Hallux Valgus|Hypotension, Orthostatic|Ischemic Stroke|Keratoconjunctivitis Sicca|Low Back Pain|Malaria, Falciparum|Menopause|Neuromyelitis Optica|Non-alcoholic Fatty Liver Disease|Oncology Hematological Unspecified|Oncology Unspecified|Orthostatic Intolerance|Osteoarthritis, Knee|Pseudomonas Infections|Sexually Transmitted Diseases|Staphylococcal Infections|Surgical Wound Infection|Total Knee Arthroplasty|beta-Thalassemia
Phase 1: Acute Pain|Angina Pectoris|Appendicitis|Arthritis, Infectious|Arthritis, Rheumatoid|Bacteroides Infections|Bronchiectasis|COVID-19|Clostridium Infections|Conjunctivitis|Coronary Disease|Fusobacterium Infections|Gram-Positive Bacterial Infections|Healthy Volunteers|Hypertension|Hypertriglyceridemia|Idiopathic Pulmonary Fibrosis|Keratitis|Myocardial Infarction|Pelvic Infection|Pelvic Inflammatory Disease|Pneumococcal Infections|Pyelonephritis|Type 2 Diabetes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2023-506031-15-01 |
SRB2021260 | P2 |
Recruiting |
Cardiac Arrest |
2030-11-30 |
2025-05-02 |
Treatments |
|
2022-500293-34-01 |
EVENEW | P2 |
Recruiting |
Bronchopulmonary Dysplasia |
2028-06-30 |
2025-05-02 |
Treatments |
|
2025-522558-37-00 |
2025-522558-37-00 | P2 |
Not yet recruiting |
Menopause |
2028-05-31 |
|||
NCT07077746 |
HBCD01 | P2 |
Recruiting |
Crohn Disease |
2027-12-01 |
12% |
2025-09-10 |
Primary Endpoints |
2023-504840-32-00 |
CN008-0003 | P2 |
Active, not recruiting |
Alzheimer Disease |
2027-11-16 |
2025-05-02 |
Treatments |
|
NCT05952804 |
RG1123550 | P2 |
Recruiting |
Oncology Unspecified|Oncology Hematological Unspecified |
2027-07-31 |
83% |
2025-04-24 |
Primary Endpoints|Treatments |
2024-514903-33-00 |
2024-514903-33-00 | P2 |
Active, not recruiting |
Osteoarthritis, Knee|Total Knee Arthroplasty |
2027-06-01 |
2025-05-02 |
Treatments |
|
2024-519366-52-00 |
IP-001-24 | P2 |
Not yet recruiting |
Kidney Diseases |
2027-06-01 |
|||
2023-509261-20-00 |
MOZEG | P2 |
Not yet recruiting |
Ischemic Stroke |
2027-03-03 |
2025-05-02 |
Treatments |
|
NCT07385287 |
BFSPZL2 | P2 |
Not yet recruiting |
Malaria, Falciparum |
2026-12-01 |
2026-02-05 |
Primary Endpoints|Treatments |
|
NCT06606561 |
NVL-2024-257 | P2 |
Not yet recruiting |
Osteoarthritis, Knee |
2026-04-01 |
50% |
2025-06-06 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
2024-513828-42-00 |
2024-513828-42-00 | P2 |
Recruiting |
CADASIL |
2026-03-31 |
2025-05-02 |
Treatments |
|
NCT06188663 |
STOOD | P2 |
Recruiting |
Orthostatic Intolerance|Hypotension, Orthostatic |
2026-03-01 |
2024-07-05 |
||
2025-521522-15-00 |
APISLIT-DD-D-2025-01 | P2 |
Not yet recruiting |
Environmental Hypersensitivity|Rhinitis, Allergic|Conjunctivitis, Allergic|Dust mite Hypersensitivity |
2026-02-02 |
|||
2023-507249-27-00 |
FTP-CLIN-01 | P2 |
Recruiting |
Glabellar Reflex |
2026-01-27 |
2025-05-02 |
Treatments |
|
CTR20243840 |
CTR20243840 | P2 |
Completed |
Anesthesia Related |
2026-01-05 |
2026-02-01 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
2023-506589-30-00 |
VAC52416BAC3001 | P3 |
Active, not recruiting |
Urinary Tract Infections |
2029-06-30 |
60% |
2025-05-02 |
Treatments |
2023-510030-83-00 |
GTi1201 | P3 |
Active, not recruiting |
Emphysema|alpha 1-Antitrypsin Deficiency |
2026-08-12 |
2025-05-02 |
Treatments |
|
2024-512388-29-00 |
FGTW2101 | P3 |
Recruiting |
Injuries/wounds Unspecified |
2026-04-30 |
2025-05-02 |
Treatments |
|
2022-501717-31-00 |
2022-501717-31-00 | P3 |
Not yet recruiting |
Small Fiber Neuropathy |
2027-12-31 |
2025-05-02 |
Treatments |
|
2024-512658-41-00 |
CQ-001-19 | P3 |
Recruiting |
Heart Failure |
2027-04-01 |
2025-05-02 |
Treatments |
|
2023-509137-39-00 |
MK-3475-091 | P3 |
Active, not recruiting |
Non-Small-Cell Lung Cancer|Small Cell Lung Cancer |
2027-02-02 |
2025-05-02 |
Treatments |
|
2025-522046-42-00 |
NER1006-01/2025 | P3 |
Not yet recruiting |
Other |
2027-01-06 |
10% |
||
2023-504942-75-01 |
PM/0059 | P3 |
Active, not recruiting |
Environmental Hypersensitivity|Dust mite Hypersensitivity|Conjunctivitis, Allergic|Asthma, Allergic|Rhinitis, Allergic |
2026-08-31 |
2025-05-02 |
Treatments |
|
2023-509105-72-00 |
C4601003 | P3 |
Active, not recruiting |
Lyme Disease |
2025-12-31 |
59% |
2025-05-02 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/11/2026 |
News Article |
BROXO Introduces Brand Update Across Water Treatment Markets |
|
03/11/2026 |
News Article |
BROXO Introduces Brand Update Across Water Treatment Markets |
|
03/06/2026 |
News Article |
Perspire Sauna Studio Launches Halotherapy Nationwide |
|
02/03/2026 |
News Article |
In HelloNation, Auto Repair Expert Clint Ferrel of Rochester Explains Brake Replacement Needs |
